[Viral clearance in wild-type hepatitis B virus after treatment with pegylated interferon alpha-2a].
López López
M Pilar
MP
Rincón Fuentes
José Pablo
JP
Rabell Iñigo
Susana
S
González Pérez-Crespo
Cristina
C
Rodríguez Gil
Francisco Javier
FJ
Jorge Vidal
Vanessa
V
Morán Sánchez
Senador
S
Nicolás Del Prado
M Isabel
MI
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D006510:Hepatitis B Antibodies / Q000097:blood; D006511:Hepatitis B Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000302:isolation & purification*; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D000077190:Interferon alpha-2; D000068576:Interferon beta-1b; D016898:Interferon-alpha / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use; D008111:Liver Function Tests; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications / Q000188:drug therapy; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D019562:Viral Load
D000998:Antiviral Agents; D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D011092:Polyethylene Glycols; D016899:Interferon-beta; C100416:peginterferon alfa-2a